This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female patients aged ≥18 years.
* Willing and able to provide written informed consent to participate in the study.
* Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
* eGFR \<60 mL/min/1.73 m² for ≥3 months, OR
* Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months
Exclusion Criteria:
* Having a life-threatening comorbidity with life expectancy \< 2 years.
* Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
* Pregnant or breastfeeding women.
* Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
* Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
Primary outcome measure(s)
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively — baseline To determine the prevalence of HP, HF, HTN, and HK among patients with CKD
Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i) — Week 0 to week 96 To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients with HK — Week 0 to week 96 To describe HK outcomes of HK recurrence for all CKD patients with HK.
Clinical outcomes of CKD patients with HK — Week 0 to week 96 To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK.
Clinical outcomes of CKD patients with HK — Week 0 to week 96 To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of Percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of Percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of Proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of Proportion of patients achieving UPCR \< 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK — Week 0 to week 96 To describe the clinical indicators of Proportion of patients achieving UPER \<1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients with HP and HTN — Week 0 to week 96 To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HP and HTN — Week 0 to week 96 To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HP and HTN — Week 0 to week 96 To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HF — Week 0 to week 96 To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the additional clinical composite outcome of eGFR decline ≥40% for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the additional clinical composite outcome of ESRD for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the additional clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the additional clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the renal outcome of ≥40% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK — Week 0 to week 96 To describe the HK outcome of new-onset HK for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients with HF — Week 0 to week 96 To describe the clinical indicators of Change of BNP from baseline over time in patients with CKD with HF.
Trial sites (59)
Facility
City
Region
Status
Research Site
Anning, Yunnan - South Region
China
Recruiting
Research Site
Beijing, Beijing
China
Recruiting
Research Site
Cangzhou, Hebei - North Region
China
Recruiting
Research Site
Caoxian County, Shandong Province
China
Recruiting
Research Site
Changzhou, Jiangsu Province
China
Recruiting
Research Site
Chengdu, Sichuan Province
China
Recruiting
Research Site
Chongqing, Chongqing
China
Recruiting
Research Site
Chongqing, Sichuan Province
China
Recruiting
Research Site
Dalian, Liaoning
China
Not Yet Recruiting
Research Site
Dongguan, Guangdong
China
Recruiting
Research Site
Foshan, Guangdong
China
Recruiting
Research Site
Fuzhou, Fujian
China
Recruiting
Research Site
Ganzhou, Jiangxi
China
Recruiting
Research Site
Guangzhou, Guangdong
China
Recruiting
Research Site
Guangzhou, Guangdong
China
Not Yet Recruiting
Research Site
Guiyang, Guizhou
China
Recruiting
Research Site
Hangzhou, Zhejiang
China
Recruiting
Research Site
Harbin, Heilongjiang
China
Recruiting
Research Site
Hohhot, Inner Mongolia
China
Not Yet Recruiting
Research Site
Huai An, Jiangsu Province
China
Recruiting
Research Site
Jiaozuo, Henan Province
China
Recruiting
Research Site
Jinan, Shandong Province
China
Recruiting
Research Site
Jining, Shandong Province
China
Recruiting
Research Site
Jiujiang, Jiangxi
China
Recruiting
Research Site
Kunming, Yunnan
China
Recruiting
Research Site
Nanchang, Jiangxi
China
Recruiting
Research Site
Nanjing, Jiangsu Province
China
Recruiting
Research Site
Nanning, Guangxi
China
Recruiting
Research Site
Nanping, Fujian
China
Recruiting
Research Site
Nantong, Jiangsu Province
China
Recruiting
Research Site
Nanyang, Henan Province
China
Recruiting
Research Site
Shanghai, Shanghai
China
Recruiting
Research Site
Shangqiu, Henan Province
China
Recruiting
Research Site
Shantou, Guangdong
China
Recruiting
Research Site
Shaoxing, Zhejiang
China
Recruiting
Research Site
Shenyang, Liaoning
China
Not Yet Recruiting
Research Site
Shenzhen, Guangdong
China
Recruiting
Research Site
Shijiazhuang, Hebei
China
Recruiting
Research Site
Shijiazhuang, Hebei
China
Not Yet Recruiting
Research Site
Suzhou, Jiangsu Province
China
Recruiting
+ 19 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.